Elpek GO. Tata-box-binding protein-associated factor 15 as a new potential marker in gastrointestinal tumors. World J Gastroenterol 2024; 30(28): 3367-3372 [DOI: 10.3748/wjg.v30.i28.3367]
Corresponding Author of This Article
Gulsum Ozlem Elpek, MD, Professor, Department of Pathology, Akdeniz University Medical School, Dumlupinar Bulvarı, Antalya 07070, Türkiye. elpek@akdeniz.edu.tr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 28, 2024; 30(28): 3367-3372 Published online Jul 28, 2024. doi: 10.3748/wjg.v30.i28.3367
Tata-box-binding protein-associated factor 15 as a new potential marker in gastrointestinal tumors
Gulsum Ozlem Elpek
Gulsum Ozlem Elpek, Department of Pathology, Akdeniz University Medical School, Antalya 07070, Türkiye
Author contributions: Elpek GO performed the design of the article, obtained, analyzed and interpreted the data, and wrote the article.
Conflict-of-interest statement: There is no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gulsum Ozlem Elpek, MD, Professor, Department of Pathology, Akdeniz University Medical School, Dumlupinar Bulvarı, Antalya 07070, Türkiye. elpek@akdeniz.edu.tr
Received: May 25, 2024 Revised: June 19, 2024 Accepted: July 2, 2024 Published online: July 28, 2024 Processing time: 60 Days and 6.5 Hours
Abstract
In this editorial, the roles of tata-box-binding protein-associated factor 15 (TAF15) in oncogenesis, tumor behavior, and as a therapeutic target in cancers in the context of gastrointestinal (GI) tumors are discussed concerning the publication by Guo et al. TAF15 is a member of the FET protein family with a comprehensive range of cellular processes. Besides, evidence has shown that TAF15 is involved in many diseases, including cancers. TAF15 contributes to carcinogenesis and tumor behavior in many tumors. Besides, its relationship with the mitogen-activated protein kinases (MAPK) signaling pathway makes TAF15 a new target for therapy. Although, the fact that there is few studies investigating the expression of TAF15 constitutes a potential limitation in GI system, the association of TAF15 expression with aggressive tumor behavior and, similar to other organ tumors, the influence of TAF15 on the MAPK signaling pathway emphasize that this protein could serve as a new molecular biomarker to predict tumor behavior and target therapeutic intervention in GI cancers. In conclusion, more studies should be performed to better understand the prognostic and therapeutic role of TAF15 in GI tumors, especially in tumors resistant to therapy.
Core Tip: Recently, the role of tata-binding protein associated factor 15 (TAF15) in many diseases, including cancer, has been suggested. Current results support the hypothesis that TAF15 expression is related to aggressive behavior by contributing to many pathways that are involved in tumor progression. Although its role in prognosis has not been entirely determined in gastrointestinal cancers, the fact that increased TAF15 expression is associated with adverse clinicopathological parameters warrants further study with the aim of better understanding its role in predicting prognosis. Moreover, based on its association with the mitogen-activated protein kinases signal pathway, its significance as a therapeutic target, particularly in tumors resistant to treatment awaits investigation.
